Tan Shuhua, Wu Wutong, Li Xiangyu, Cui Li, Li Bing, Ruan Qiping
School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, P.R. China.
Mol Biotechnol. 2007 May;36(1):1-8. doi: 10.1007/s12033-007-0002-8.
It has been previously shown that Escherichia coli L-asparaginase II (L-ASP) signal peptide is capable of being utilized to direct extracellular secretion of hirudin III (HV3) in shake flask. In this study HV3 muteins R33G34D35(S36)-HV3 were generated by introduction of adhesive recognition sequence RGD(S) into the non-functional region of HV3. The resultant recombinants were cultivated on 30 l bioreactor scale using L-ASP signal peptide expression system and the optimized fed-batch cultivation was well established. After cultivation for approximately 11 h the secreted product accumulated up to approximately 1 g l(-1), which means 17-fold increase in productivity compared to initial expression in shake flask. N-terminal analysis, pI measurement, and MALDI mass spectral analysis on mutein R33G34D35S36-HV3 confirmed the authenticity of the product. Compared to wild-type HV3 and R33G34D35HV3, the mutein R33G34D35S36-HV3 exhibits the improved pharmacological activity. Collectively, a novel secretion strategy using L-ASP signal peptide for the rapid, efficient and cost-effective production of HV3 mutein possessing improved pharmacological activity on bioreactor scale has been well established. Using this expression system downstream processing becomes very simple because secreted product is mature, soluble, active, and without N-terminal extension of Met, which is quite critical for most therapeutic protein to reduce the side effect in clinic use. Thus, it provides a promising alternative for extracellular production of other difficult-to-express protein for biopharmaceutical use.
先前的研究表明,大肠杆菌L-天冬酰胺酶II(L-ASP)信号肽能够用于在摇瓶中指导水蛭素III(HV3)的细胞外分泌。在本研究中,通过将黏附识别序列RGD(S)引入HV3的非功能区,产生了HV3突变体R33G34D35(S36)-HV3。使用L-ASP信号肽表达系统在30 L生物反应器规模上培养所得重组体,并建立了优化的补料分批培养方法。培养约11小时后,分泌产物积累至约1 g L-1,这意味着与在摇瓶中的初始表达相比,生产率提高了17倍。对突变体R33G34D35S36-HV3进行的N端分析、pI测量和基质辅助激光解吸电离质谱分析证实了产物的真实性。与野生型HV3和R33G34D35HV3相比,突变体R33G34D35S36-HV3表现出改善的药理活性。总的来说,已经成功建立了一种使用L-ASP信号肽的新型分泌策略,用于在生物反应器规模上快速、高效且经济高效地生产具有改善药理活性的HV3突变体。使用该表达系统,下游处理变得非常简单,因为分泌产物是成熟的、可溶的、有活性的,并且没有N端甲硫氨酸延伸,这对于大多数治疗性蛋白质在临床使用中减少副作用非常关键。因此,它为生物制药用途的其他难以表达的蛋白质的细胞外生产提供了一种有前景的替代方法。